EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer
In non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation, 50%–65% of cases acquire resistance after treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) because of an EGFR T790M point mutation and 3%–14% of these cases transformed to small cell lung cancer...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-01-01
|
Series: | Respiratory Medicine Case Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213007117303921 |
id |
doaj-000ec2f71d2e41b28a3a89faf0415923 |
---|---|
record_format |
Article |
spelling |
doaj-000ec2f71d2e41b28a3a89faf04159232020-11-24T21:21:46ZengElsevierRespiratory Medicine Case Reports2213-00712018-01-01241921EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancerTomoaki Sonoda0Shingo Nishikawa1Rie Sakakibara2Masafumi Saiki3Ryo Ariyasu4Junji Koyama5Satoru Kitazono6Noriko Yanagitani7Atsushi Horiike8Fumiyoshi Ohyanagi9Hironori Ninomiya10Yuichi Ishikawa11Makoto Nishio12Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, JapanDepartment of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, JapanDivision of Pathology, The Cancer Institute of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, JapanDepartment of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, JapanDepartment of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, JapanDepartment of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, JapanDepartment of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, JapanDepartment of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, JapanDepartment of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, JapanDivision of Pulmonary Medicine, Clinical Department of Internal Medicine, Jichi Medical University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama-shi, Saitama-ken, JapanDivision of Pathology, The Cancer Institute of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, JapanDivision of Pathology, The Cancer Institute of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, JapanDepartment of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo 135-8550, Japan; Corresponding author.In non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation, 50%–65% of cases acquire resistance after treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) because of an EGFR T790M point mutation and 3%–14% of these cases transformed to small cell lung cancer (SCLC). Generally, the EGFR T790M secondary mutation develops with ongoing ATP competitive inhibition. We present a case of a 76-year-old woman with lung adenocarcinoma harboring an EGFR-L858R mutation who received first-line gefitinib and developed SCLC transformation. She was administered several chemotherapy agents, including a platinum doublet. The primary lesion that showed SCLC transformation had reconverted to adenocarcinoma with EGFR L858R and T790M mutations at the time of a second re-biopsy. Therefore, she was administered osimertinib, which resulted in clinical remission. This case suggested that serial biopsies are necessary even after SCLC transformation. Keywords: NSCLC, EGFR mutation, SCLC transformation, T790M, Osimertinibhttp://www.sciencedirect.com/science/article/pii/S2213007117303921 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Tomoaki Sonoda Shingo Nishikawa Rie Sakakibara Masafumi Saiki Ryo Ariyasu Junji Koyama Satoru Kitazono Noriko Yanagitani Atsushi Horiike Fumiyoshi Ohyanagi Hironori Ninomiya Yuichi Ishikawa Makoto Nishio |
spellingShingle |
Tomoaki Sonoda Shingo Nishikawa Rie Sakakibara Masafumi Saiki Ryo Ariyasu Junji Koyama Satoru Kitazono Noriko Yanagitani Atsushi Horiike Fumiyoshi Ohyanagi Hironori Ninomiya Yuichi Ishikawa Makoto Nishio EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer Respiratory Medicine Case Reports |
author_facet |
Tomoaki Sonoda Shingo Nishikawa Rie Sakakibara Masafumi Saiki Ryo Ariyasu Junji Koyama Satoru Kitazono Noriko Yanagitani Atsushi Horiike Fumiyoshi Ohyanagi Hironori Ninomiya Yuichi Ishikawa Makoto Nishio |
author_sort |
Tomoaki Sonoda |
title |
EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer |
title_short |
EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer |
title_full |
EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer |
title_fullStr |
EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer |
title_full_unstemmed |
EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer |
title_sort |
egfr t790m mutation after chemotherapy for small cell lung cancer transformation of egfr-positive non-small cell lung cancer |
publisher |
Elsevier |
series |
Respiratory Medicine Case Reports |
issn |
2213-0071 |
publishDate |
2018-01-01 |
description |
In non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation, 50%–65% of cases acquire resistance after treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) because of an EGFR T790M point mutation and 3%–14% of these cases transformed to small cell lung cancer (SCLC). Generally, the EGFR T790M secondary mutation develops with ongoing ATP competitive inhibition. We present a case of a 76-year-old woman with lung adenocarcinoma harboring an EGFR-L858R mutation who received first-line gefitinib and developed SCLC transformation. She was administered several chemotherapy agents, including a platinum doublet. The primary lesion that showed SCLC transformation had reconverted to adenocarcinoma with EGFR L858R and T790M mutations at the time of a second re-biopsy. Therefore, she was administered osimertinib, which resulted in clinical remission. This case suggested that serial biopsies are necessary even after SCLC transformation. Keywords: NSCLC, EGFR mutation, SCLC transformation, T790M, Osimertinib |
url |
http://www.sciencedirect.com/science/article/pii/S2213007117303921 |
work_keys_str_mv |
AT tomoakisonoda egfrt790mmutationafterchemotherapyforsmallcelllungcancertransformationofegfrpositivenonsmallcelllungcancer AT shingonishikawa egfrt790mmutationafterchemotherapyforsmallcelllungcancertransformationofegfrpositivenonsmallcelllungcancer AT riesakakibara egfrt790mmutationafterchemotherapyforsmallcelllungcancertransformationofegfrpositivenonsmallcelllungcancer AT masafumisaiki egfrt790mmutationafterchemotherapyforsmallcelllungcancertransformationofegfrpositivenonsmallcelllungcancer AT ryoariyasu egfrt790mmutationafterchemotherapyforsmallcelllungcancertransformationofegfrpositivenonsmallcelllungcancer AT junjikoyama egfrt790mmutationafterchemotherapyforsmallcelllungcancertransformationofegfrpositivenonsmallcelllungcancer AT satorukitazono egfrt790mmutationafterchemotherapyforsmallcelllungcancertransformationofegfrpositivenonsmallcelllungcancer AT norikoyanagitani egfrt790mmutationafterchemotherapyforsmallcelllungcancertransformationofegfrpositivenonsmallcelllungcancer AT atsushihoriike egfrt790mmutationafterchemotherapyforsmallcelllungcancertransformationofegfrpositivenonsmallcelllungcancer AT fumiyoshiohyanagi egfrt790mmutationafterchemotherapyforsmallcelllungcancertransformationofegfrpositivenonsmallcelllungcancer AT hironorininomiya egfrt790mmutationafterchemotherapyforsmallcelllungcancertransformationofegfrpositivenonsmallcelllungcancer AT yuichiishikawa egfrt790mmutationafterchemotherapyforsmallcelllungcancertransformationofegfrpositivenonsmallcelllungcancer AT makotonishio egfrt790mmutationafterchemotherapyforsmallcelllungcancertransformationofegfrpositivenonsmallcelllungcancer |
_version_ |
1725998329216630784 |